Review ArticlesRenal Sympathetic Denervation for the Treatment of Systemic HypertensionBurke, Gordon M. MD*; Sica, Domenic A. MD†; Frishman, William H. MD‡ Author Information From the *Department of Internal Medicine, Boston University Medical Center, Boston, MA; †Department of Medicine & Pharmacology, Div. of Nephrology, Virginia, Commonwealth University Health System, Richmond, VA; and ‡Department of Medicine, New York Medical College/Westchester Medical Center, Valhalla, NY. Disclosure: The authors have no conflicts of interest to report. Correspondence: William H. Frishman MD, Dept. of Medicine, New York Medical College, Valhalla, NY 10595. E-mail: [email protected]. Cardiology in Review 20(6):p 274-278, November/December 2012. | DOI: 10.1097/CRD.0b013e3182651f91 Buy Metrics Abstract Systemic hypertension is a common cardiovascular problem that often cannot be fully treated with existing nonpharmacologic and pharmacologic measures. A catheter-based strategy which denervates the renal afferent and efferent autonomic nervous system has been developed for the treatment of drug-resistant hypertension. In early clinical trials, this procedure was shown to be both feasible and safe in reducing blood pressure in patients with uncontrolled hypertension receiving treatment with a minimum of 3 antihypertensive drugs. In addition, this procedure has been associated with decreased renin secretion, preservation of renal function, improved glucose tolerance, and a reduction in left ventricular hypertrophy. The long-term effects of this procedure (beyond 3 years) still need to be determined. A large 530-patient sham-controlled trial is now in progress. © 2012 Lippincott Williams & Wilkins, Inc.